CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.

Autor: Sam J; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Hofer T; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Kuettel C; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Claus C; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Thom J; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Herter S; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Georges G; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany., Korfi K; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Lechmann M; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany., Eigenmann MJ; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Marbach D; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Jamois C; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Lechner K; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany., Krishnan SM; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Gaillard B; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Marinho J; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Kronenberg S; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Kunz L; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Wilson S; Roche Innovation Center Welwyn, Roche Pharma Research and Early Development, Welwyn Garden City, United Kingdom., Briner S; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Gebhardt S; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Varol A; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Appelt B; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Nicolini V; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Speziale D; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Bez M; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Bommer E; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Eckmann J; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany., Hage C; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany., Limani F; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Jenni S; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Schoenle A; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Le Clech M; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Vallier JP; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Colombetti S; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Bacac M; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Gasser S; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Klein C; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Umaña P; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland.

Publikováno v: Blood [Blood] 2024 May 23; Vol. 143 (21), pp. 2152-2165.

Assessing CaMPARI as new approach methodology for evaluating neurotoxicity.

Autor: Biechele-Speziale D; Department of Chemistry, Brown University, Providence, RI, USA; Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA., Camarillo M; Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA., Martin NR; Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA., Biechele-Speziale J; School of Industrial Engineering, Purdue University, West Lafayette, IN, USA., Lein PJ; Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA, USA., Plavicki JS; Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA. Electronic address: jessica_plavicki@brown.edu.

Publikováno v: Neurotoxicology [Neurotoxicology] 2023 Jul; Vol. 97, pp. 109-119. Date of Electronic Publication: 2023 May 25.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A New PCR-Based Assay for Testing Bronchoalveolar Lavage Fluid Samples from Patients with Suspected Pneumocystis jirovecii Pneumonia.

Autor: Liotti FM; Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Roma, Italy.; Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Roma, Italy., Posteraro B; Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Roma, Italy.; Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Roma, Italy., De Angelis G; Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Roma, Italy.; Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Roma, Italy., Torelli R; Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Roma, Italy., De Carolis E; Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Roma, Italy., Speziale D; Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Roma, Italy., Menchinelli G; Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Roma, Italy.; Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Roma, Italy., Spanu T; Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Roma, Italy.; Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Roma, Italy., Sanguinetti M; Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Roma, Italy.; Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Roma, Italy.

Publikováno v: Journal of fungi (Basel, Switzerland) [J Fungi (Basel)] 2021 Aug 24; Vol. 7 (9). Date of Electronic Publication: 2021 Aug 24.

Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity.

Autor: Sum E; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland., Rapp M; Roche Innovation Center Munich (RICM), pRED, Penzberg, Germany., Fröbel P; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland., Le Clech M; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland., Dürr H; Roche Innovation Center Munich (RICM), pRED, Penzberg, Germany., Giusti AM; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland., Perro M; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland., Speziale D; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland., Kunz L; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland., Menietti E; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland., Brünker P; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland., Hopfer U; Roche Innovation Center Basel (RICB), pRED, Basel, Switzerland., Lechmann M; Roche Innovation Center Munich (RICM), pRED, Penzberg, Germany., Sobieniecki A; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland., Appelt B; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland., Adelfio R; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland., Nicolini V; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland., Freimoser-Grundschober A; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland., Jordaan W; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland., Labiano S; Department of Fundamental Oncology, University of Lausanne, Epalinges, Switzerland., Weber F; Roche Innovation Center Basel (RICB), pRED, Basel, Switzerland., Emrich T; Roche Innovation Center Munich (RICM), pRED, Penzberg, Germany., Christen F; Roche Innovation Center Basel (RICB), pRED, Basel, Switzerland., Essig B; Roche Innovation Center Munich (RICM), pRED, Penzberg, Germany., Romero P; Department of Fundamental Oncology, University of Lausanne, Epalinges, Switzerland., Trumpfheller C; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland. pablo.umana@roche.com christine.trumpfheller@roche.com., Umaña P; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland. pablo.umana@roche.com christine.trumpfheller@roche.com.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jul 15; Vol. 27 (14), pp. 4036-4053. Date of Electronic Publication: 2021 Mar 26.